Risk factors

Company is a clinical-stage biopharmaceutical firm reliant on novel allogeneic T cell therapies and gene editing technologies. It faces substantial financing needs, manufacturing hurdles, and reliance on key partners like Cellectis and Foresight Diagnostics.

Alto Ingredients faces heavy exposure to corn and natural gas price volatility affecting its alcohol and essential ingredient production.

Manufacturing is concentrated in Clearwater, Florida and Sofia, Bulgaria, exposing operations to weather and supply chain disruptions. Recurring net losses raise going concern doubts, necessitating potential capital raises or operating expenditure cuts. Commercial success heavily depends on demand for elective cosmetic procedures utilizing the Renuvion and AYON technologies.

Collecting less-than-prime receivables and securing borrowed funding dominate the company’s financial risks.

The company faces extensive clinical trial, regulatory, and manufacturing risks as a pre-commercial biotherapeutics firm dependent on efzofitimod. There is no established FDA regulatory pathway for pulmonary sarcoidosis, threatening approval even if trials succeed. The firm relies entirely on third-party contract manufacturers and clinical research organizations.

Accumulated deficit of $173.8 million and 2024 operating loss of $14.3 million threaten ongoing operations.

Aveanna Healthcare Holdings relies heavily on government reimbursement rates from Medicare and Medicaid, which fund its home health, hospice, and pediatric services.

Revenue depends heavily on unpredictable individual orders, government contracts, and third-party channel partners selling biometric software. Adoption of biometrics in commercial markets remains uncertain amid intense competition and rapid technological changes. Reliance on open-source code, third-party software, cloud models, and key personnel creates operational and intellectual property risks.

BCP Investment Corp operates as a BDC, subject to leverage risks via its Revolving Credit Facility and 4.875% Notes due 2026. The company faces significant integration, litigation, and closing risks related to its pending merger with LRFC announced on January 29, 2025. Valuation uncertainty persists due to illiquid portfolio investments, Joint Ventures, and CLO Funds recorded at fair value.

HeartBeam faces going-concern doubts from auditors alongside a complete lack of current revenues. The company requires significant capital raises to fund ongoing product development and commercialization. Regulatory approvals, third-party reimbursement, and physician adoption are critical hurdles for future viability.

Blend Labs depends heavily on the financial services and mortgage industries, facing interest rate volatility and an accumulated deficit of $1,385.0 million as of December 31, 2024.

Brilliant Earth operates in fine jewelry with high reliance on precious materials and third-party suppliers. Growth depends heavily on e-commerce, showroom expansion, and repeat customers. Debt obligations to Silicon Valley Bank and compliance with ESG standards remain critical.